GENE ONLINE|News &
Opinion
Blog

2025-11-27|

Researchers Develop Pectin Microparticles with Probiotics and Glycyrrhizin to Combat Dental Caries

by GOAI
Share To

Researchers have explored the use of mucoadhesive pectin microparticles as a potential method for managing dental caries, a widespread oral health issue affecting millions globally. The study focuses on combining pectin, a natural polysaccharide, with probiotics such as *Lactobacillus rhamnosus* and *Lactobacillus casei*, along with bioactive compounds including glycyrrhizin and vitamin D3. This approach aims to address dental caries by leveraging the antimicrobial and health-promoting properties of these components.

The research highlights the adhesive properties of pectin microparticles, which allow them to bind effectively to oral surfaces, potentially enhancing their ability to deliver active ingredients directly to affected areas. The inclusion of probiotics like *Lactobacillus rhamnosus* and *Lactobacillus casei* is intended to support oral microbiome balance, while glycyrrhizin—a compound derived from licorice root—offers anti-inflammatory and antimicrobial benefits. Vitamin D3 is included for its role in promoting overall oral health. Researchers suggest that this combination could provide a targeted strategy for preventing or managing dental caries by addressing both bacterial activity and oral tissue health. Further studies are expected to evaluate the efficacy and safety of this innovative treatment approach.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

For any suggestion and feedback, please contact us.

Date: November 27, 2025

©www.geneonline.com All rights reserved. Collaborate with us: [email protected]
Author
Related Post
Taiwan Healthcare Expo Opens With €200 Million Czech Deal as Global Buyers Flock to Taipei
2025-12-07
LATEST
Taiwan Healthcare Expo Opens With €200 Million Czech Deal as Global Buyers Flock to Taipei
2025-12-07
AI-Driven Healthcare Transformation at Healthcare Expo Taiwan 2025
2025-12-05
How AWS Cloud Is Transforming Global Smart Healthcare and Trusted Research Environments
2025-12-03
MedTex 2025: Taiwan as Gateway for AI-Driven Medical Innovation and Global Capital
2025-12-03
FDA CBER Director Vinay Prasad Issues November 2025 Memo Addressing Vaccine Development and Regulatory Challenges
2025-12-03
FDA to Review 16 Drug Applications Including 8 New Molecular Entities by Year-End
2025-12-03
Stephen Durso Named CEO of Altimmune Inc. as Vipin Garg Steps Down
2025-12-03
EVENT
2025-12-06
The 67th ASH Annual Meeting and Exposition
Orlando, Florida, USA
Scroll to Top